Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0DJWUP
ADC Name
Quinoin cetuximab immunoconjugate
Synonyms
Quinoin-cetuximab immunoconjugate
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Colorectal cancer [ICD11:2B91]
Investigative
Drug-to-Antibody Ratio
1-2
Antibody Name
Cetuximab
  Antibody Info 
Antigen Name
Epidermal growth factor receptor (EGFR)
  Antigen Info 
Payload Name
Quinoin
  Payload Info 
Therapeutic Target
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)
  Target Info 
Linker Name
N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)
  Linker Info 
Conjugate Type
Chemical disulphide bridge between cetuximab and quinoin.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
27.7
nM
GEO cells (Cetuximab-resistant)
Colon carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 27.70 nM Positive EGFR expression (EGFR +++/++)
Method Description
Cells were treated with different concentrations of drugs for 72 h. The viability was determined using the MTT assay.
In Vitro Model Colon carcinoma GEO cells (Cetuximab-resistant) CVCL_0271
References
Ref 1 A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells. Toxins (Basel). 2023 Jan 9;15(1):57. doi: 10.3390/toxins15010057.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.